Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Escherichia coli | penicillin-binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium tuberculosis | Possible penicillin-binding protein | Get druggable targets OG5_149948 | All targets in OG5_149948 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | S-adenosylhomocysteine hydrolase | 0.026 | 0.2883 | 0.5 |
Loa Loa (eye worm) | adenosylhomocysteinase | 0.026 | 0.2883 | 0.5 |
Echinococcus granulosus | adenosylhomocysteinase | 0.026 | 0.2883 | 0.5 |
Entamoeba histolytica | adenosylhomocysteinase, putative | 0.026 | 0.2883 | 0.5 |
Plasmodium falciparum | adenosylhomocysteinase | 0.026 | 0.2883 | 0.5 |
Trypanosoma cruzi | S-adenosylhomocysteine hydrolase, putative | 0.026 | 0.2883 | 0.5 |
Plasmodium vivax | adenosylhomocysteinase(S-adenosyl-L-homocystein e hydrolase), putative | 0.026 | 0.2883 | 0.5 |
Trypanosoma brucei | S-adenosylhomocysteine hydrolase, putative | 0.026 | 0.2883 | 0.5 |
Trypanosoma cruzi | S-adenosylhomocysteine hydrolase, putative | 0.026 | 0.2883 | 0.5 |
Schistosoma mansoni | adenosylhomocysteinase | 0.026 | 0.2883 | 1 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.026 | 0.2883 | 1 |
Mycobacterium ulcerans | S-adenosyl-L-homocysteine hydrolase | 0.026 | 0.2883 | 0.5 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0278 | 0.317 | 1 |
Mycobacterium leprae | putative S-adenosyl-L-homocysteine hydrolase SahH | 0.026 | 0.2883 | 0.5 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.026 | 0.2883 | 1 |
Echinococcus multilocularis | adenosylhomocysteinase | 0.026 | 0.2883 | 0.5 |
Brugia malayi | Adenosylhomocysteinase | 0.026 | 0.2883 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 1.4125 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 4.1475 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.